- 1 Unravelling the determinants of human health in French Polynesia: the MATAEA
- 2 project
- 3 **<u>Running title:</u>** Health determinants in French Polynesia
- 4 Iotefa Teiti^{1†}, Maite Aubry^{1†}, Sandrine Fernandes-Pellerin², Etienne Patin³, Yoann Madec⁴,
- 5 Pauline Boucheron⁴, Jessica Vanhomwegen⁵, Jérémie Torterat⁶, Stéphane Lastère⁷, Sophie
- 6 Olivier⁸, Anthony Jaquaniello^{3,9}, Maguelonne Roux^{3,10}, Vincent Mendiboure⁴, Christine
- Harmant³, Aurélie Bisiaux³, Gaston Rijo de León³, Dang Liu³, Hervé Bossin¹¹, Françoise
 Mathieu-Daudé^{11,12}, Clémence Gatti¹³, Edouard Suhas¹⁴, Kivojiken Chung¹, Bertrand Condat¹⁵.
- Mathieu-Daudé^{11,12}, Clémence Gatti¹³, Edouard Suhas¹⁴, Kiyojiken Chung¹, Bertrand Condat¹⁵,
 Pierre Ayotte¹⁶, Nicolas Prud'homme⁶, Eric Conte¹⁷, Nathalie Jolly², Jean-Claude Manugerra⁵,
- 10 Anavaj Sakuntabhai¹⁸, Arnaud Fontanet^{4,19§}, Lluis Quintana-Murci^{3,20§}, Van-Mai Cao-
- 10 Anavaj Sakuntaonai , Arnauu Fontanet^{1,2,5}, Liuis Quintana-Murci^{1,2,5}, van-Mai Cao-11 Lormeau^{1§*}
- ¹ Laboratory of research on emerging viral diseases, Institut Louis Malardé, Papeete, Tahiti, French
- 13 Polynesia
- 14 ² Center for Translational Sciences, Institut Pasteur, Paris, France
- 15 ³ Institut Pasteur, Université Paris Cité, CNRS UMR2000, Human Evolutionary Genetics Unit, F-
- 16 75015 Paris, France
- ⁴ Institut Pasteur, Université Paris Cité, Epidemiology of emerging diseases unit, 75015 Paris, France
- 18 ⁵ Environment and Infectious Risk Unit, Laboratory for Urgent Response to Biological Threats, Institut
- 19 Pasteur, Paris, France
- ⁶ Institut de la Statistique de la Polynésie française, Papeete, Tahiti, French Polynesia
- ⁷ Clinical Laboratory, Centre hospitalier de Polynésie française, Pirae, Tahiti, French Polynesia
- ⁸ Clinical Laboratory, Institut Louis Malardé, Papeete, Tahiti, French Polynesia
- ⁹ Institut Pasteur, Data Management Core Facility, Paris, France
- ¹⁰ Institut Pasteur, Université de Paris, Bioinformatics and Biostatistics Hub, F-75015 Paris, France
- ¹¹ Laboratory of research in medical entomology, Institut Louis Malardé, Paea, Tahiti, French
 Polynesia
- ¹² MIVEGEC, University of Montpellier, CNRS, IRD, Montpellier, France
- 28 ¹³ Laboratory of Marine Biotoxins, UMR241-Ecosystèmes Insulaires Océaniens (EIO) (IFREMER,
- 29 ILM, IRD, UPF), Institut Louis Malardé, Papeete, Tahiti, French Polynesia
- 30 ¹⁴ Unit on non-communicable diseases, UMR241-Ecosystèmes Insulaires Océaniens (EIO)
- 31 (IFREMER, ILM, IRD, UPF), Institut Louis Malardé, Papeete, Tahiti, French Polynesia
- ¹⁵ Department of Gastroenterology, Centre hospitalier de Polynésie française, Pirae, Tahiti, French
 Polynesia
- ¹⁶ Centre de Toxicologie du Québec, Institut National de Santé Publique du Québec, Québec, Canada
- ¹⁷ Maison des Sciences de l'Homme du Pacifique, Université de la Polynésie française, Punaauia,
 Tahiti, French Polynesia
- ¹⁸ Functional Genetics of Infectious Diseases Unit, Department of Global Health, Institut Pasteur, Paris
- 38 Cedex 15, France
- 39 ¹⁹ PACRI unit, Conservatoire National des Arts et Métiers, Paris, France
- 40 ²⁰ Chair Human Genomics and Evolution, Collège de France, Paris 75005, France
- 41 *** Correspondence:**
- 42 Van-Mai Cao-Lormeau
- 43 <u>mlormeau@ilm.pf</u>

44 [†] These authors have contributed equally to this work and share first authorship

[§] These authors have contributed equally to this work and share last authorship 45

- 46 Keywords: French Polynesia, cross-sectional survey, non-communicable diseases,
- communicable diseases, population genetics. 47
- 48

49 Abstract

50 Background: French Polynesia is a French overseas collectivity in the Southeast Pacific, comprising 51 75 inhabited islands across five archipelagoes. The human settlement of the region corresponds to the 52 last massive migration of humans to empty territories, but its timeline is still debated. Despite their 53 recent population history and geographical isolation, inhabitants of French Polynesia experience health 54 issues similar to those of continental countries. Modern lifestyles and increased longevity have led to 55 a rise in non-communicable diseases (NCDs) such as obesity, diabetes, hypertension, and 56 cardiovascular diseases. Likewise, international trade and people mobility have caused the emergence 57 of communicable diseases (CDs) including mosquito-borne and respiratory diseases. Additionally, 58 chronic pathologies including acute rheumatic fever, liver diseases, and ciguatera, are highly prevalent 59 in French Polynesia. However, data on such diseases are scarce and not representative of the

- geographic fragmentation of the population. 60
- **Objectives**: The MATAEA project aims to estimate the prevalence of several NCDs and CDs in the 61
- population of the five archipelagoes, and identify associated risk factors. Moreover, genetic analyses 62
- 63 will contribute to determinate the sequence and timings of the peopling history of French Polynesia,
- 64 and identify causal links between past genetic adaptation to island environments, and present-day
- 65 susceptibility to certain diseases.
- 66 Methods: This cross-sectional survey is based on the random selection of 2,100 adults aged 18-69
- 67 years and residing on 18 islands from the five archipelagoes. Each participant answered a questionnaire 68 on a wide range of topics (including demographic characteristics, lifestyle habits and medical history),
- 69 underwent physical measurements (height, weight, waist circumference, arterial pressure, and skin
- 70 pigmentation), and provided biological samples (blood, saliva, and stool) for biological, genetic and
- 71 microbiological analyses.
- 72 Conclusion: For the first time in French Polynesia, the MATAEA project allows to collect a wide
- 73 range of data to explore the existence of indicators and/or risk factors for multiple pathologies of public
- 74 health concern. The results will help health authorities to adapt actions and preventive measures aimed
- at reducing the incidence of NCDs and CDs. Moreover, the new genomic data generated in this study, 75
- 76 combined with anthropological data, will increase our understanding of the peopling history of French Polynesia.
- 77
- 78

79 INTRODUCTION

80 French Polynesia is located in the Southeast Pacific and within the Polynesian triangle, which is bounded by the islands of Hawaii to the North, Aotearoa (New Zealand) to the West and Rapa Nui 81 82 (Easter Island) to the East. This French overseas collectivity extends over a maritime area as large as 83 Europe and includes 121 islands, of which 75 are inhabited, distributed within five archipelagoes: 84 Society, Marquesas, Tuamotu, Gambier and Austral (Figure 1). According to the previous national population census conducted in 2017, there are about 276,000 inhabitants distributed in the various 85 archipelagoes, of which nearly 75% are concentrated in the islands of Tahiti and Moorea (Windward 86 87 Islands, Society archipelago) (1).

88 In the course of the history of human migrations around the world, Pacific islands, and Polynesia in particular, were the last empty lands to be settled (2). Although archaeological and 89 90 linguistic data have provided evidence for the geographical and temporal origin of the populations of 91 the Eastern Pacific islands, the sequence and timings of settlement of the Polynesian islands are still 92 debated (3). To help elucidate these gaps, a few genetic studies including samples from Pacific 93 populations have been conducted over the past five years (2-6). However, for the studies involving the 94 use of samples from the population of French Polynesia, only a limited number of samples collected 95 in a few islands were available. Some studies also aimed to identify genomic variations related to 96 adaptation of the populations to island environments. In a study including genomes from 20 97 populations from the Pacific region, candidate variants for positive selection were found in genes 98 relating to immunity and metabolism, suggesting genetic adaptation to pathogens and food sources 99 specific to Pacific islands (4). However, further investigations are needed to identify causal links 100 between past genetic adaptation and present-day disease risk in Pacific settings. Indeed, most studies 101 investigating genetic links with vulnerabilities to non-communicable (NCDs) and communicable 102 (CDs) diseases have focused on populations in Africa, Europe, Asia, and USA (7-10). The same 103 observation is made for the research investigating the link between human gut microbiome composition 104 and susceptibility to diseases (7). Despite the high burden of various NCDs and CDs, Pacific islands 105 remain highly underrepresented in genomic studies.

106 In addition to genetic and microbial factors, social and environmental factors such as poverty, 107 education, and access to healthcare are thought to be major drivers of disease burden in the Pacific 108 islands (7). In French Polynesia, prevention measures against NCDs and CDs have been enhanced, and 109 access to healthcare has been improved in all archipelagoes over the past 3 decades (11). This has 110 certainly contributed to the extension of life expectancy at birth, which has increased from 67.1 years 111 to 74.7 for men and 72.8 years to 79.1 for women between 1990 and 2020 (12). However, modern 112 lifestyles (including overconsumption of food and physical inactivity) and increased longevity have 113 led to a rise in the incidence of NCDs (13). The most recent data collected in French Polynesia in 2010 114 indicated that the prevalence of obesity and hypertension in adults was 40.4% and 26.7%, respectively. 115 It was estimated that only 1.7% of the population of French Polynesia presented a low risk of 116 developing a NCD whereas 45% were at high risk (14). According to the latest reports from the health 117 authorities of French Polynesia, the leading causes of death are cardiovascular diseases (26.1%) mainly 118 associated with lifestyle, and cancers (25.1%) (15, 16). Among the Pacific island countries and 119 territories (PICTs), French Polynesia displayed one of the highest age-standardized cancer incidence 120 (267.9 for males and 214.0 for females per 100,000) and age-standardized cancer mortality (157.2 for 121 males and 106.8 for females per 100,000) in 2020 (17-19). The most frequently reported cancers are 122 lung, prostate, breast, thyroid and colorectal cancers (19). Moreover, the incidence of hepatocellular 123 carcinoma recorded in the Austral archipelago between 2013 and 2017 is among the highest in the 124 world (43.1/100,000 inhabitants), this pathology being associated with a high prevalence of infection 125 with hepatitis B virus (HBV) and obesity (20).

126 Dietary habits, especially high fish consumption, also expose the population of French 127 Polynesia to seafood-related NCDs. Among them, ciguatera poisoning, a disease caused by the 128 consumption of reef fishes or marine invertebrates contaminated by neurotoxins (ciguatoxins) 129 produced by the microalgae Gambierdiscus, is highly prevalent in French Polynesia where it 130 constitutes an important public health issue (21). In 2021, the overall incidence rate of ciguatera, based 131 on the number of symptomatic cases reported by healthcare workers or by the patients themselves, was 132 6.9/10,000 inhabitants (22). However, as (i) ciguatera is not on the list of notifiable diseases, (ii) a large 133 proportion of ciguatera-affected people do not consult a healthcare worker, and (iii) cases requiring 134 emergency care or hospitalization in the main hospital of French Polynesia (Centre hospitalier de 135 *Polynésie française*, Tahiti) are not systematically recorded, the true incidence rate of this disease is 136 underestimated. Another source of seafood-related contaminants are heavy metals including mercury 137 and lead. Indeed, high levels of mercury were detected in adolescents and adults from two atolls of the 138 Tuamotu archipelago (Hao and Makemo) (23), in adults from the Leeward islands (Tahiti and Moorea) 139 (24), and in cord blood samples of delivering women from all archipelagoes, suggesting that Polynesian 140 newborns may be prenatally exposed to high doses of mercury (25). Moreover, concentrations of lead 141 exceeding toxicological reference values were found in a significant proportion of the residents of Hao 142 and Makemo islands tested to assess their exposure to toxic metals and polychlorinated biphenyls 143 (PCBs) (23). Although levels of PCBs found in both atolls were low compared to international 144 standards, there was a higher body burden of PCBs in residents of Hao which was suggested to be 145 potentially linked to some contamination of the environment by military support activities in this island. Another source of environmental contamination that may have an impact on the population 146 147 health are pesticides. To our knowledge, there are no data concerning the level of exposure to pesticides 148 of the population of French Polynesia. However, surveys on the pollution of French Polynesia coral 149 reefs by pesticides found the presence of herbicides and insecticides in fishes which are commonly 150 consumed by the local inhabitants (26-28).

151 In addition to NCDs, CDs represent major health problems in French Polynesia. As a result of 152 the prevention, screening, treatment and vaccination programs implemented by the health authorities, 153 the incidence of several CDs has decreased (29). Despite these efforts, some CDs caused by bacterial 154 infections persist, including leprosy (mean incidence of 1.6 cases per 100,000 inhabitants reported from 155 2000 to 2017) and tuberculosis (incidence of 19.4 cases per 100,000 inhabitants in 2018) (30, 31). 156 Moreover, in 2013, the prevalence of Bancroftian lymphatic filariasis, an infection caused by the 157 nematode worm Wuchereria bancrofti transmitted by mosquitoes, still had not reached the elimination 158 threshold (*i.e.* filarial antigenemia <1%) defined by the World Health Organization (WHO) in Tahiti, 159 Huahine (Leeward Islands, Society archipelago) and three islands in the Marquesas archipelago 160 (Tahuata, Hiva Oa and Fatu Hiva), despite several years of community treatment (32-35). Furthermore, HBV remains a public health problem, despite the availability of an effective vaccine. Following the 161 162 finding of hepatitis B surface antigens (HBsAg) among 10.48% inhabitants of the Austral archipelago 163 randomly selected in 1987 (36), vaccination of children at birth started to be implemented in 1992 to 164 decrease the burden of chronic HBV infection in French Polynesia (37), and became mandatory in 165 1995 (38). A nationwide serosurvey conducted in 2014 in 6 years old schoolchildren from the five 166 archipelagoes showed a three-dose vaccination coverage of 98% and a prevalence of HBsAg of 0% 167 (39). However, screening in 2019 of all adult residents of Rapa, the most isolated island of the Austral 168 archipelago, revealed a prevalence of HBsAg of 11% in people born before 1992 (20).

Among the CDs considered as important public health issues in French Polynesia, those caused by arthropod-borne viruses (arboviruses) represent the highest risk for the population. Indeed, the four serotypes of dengue virus (DENV-1 to -4) have caused multiple outbreaks over the last decades, with deaths frequently reported in children (40, 41). Moreover, Zika virus (ZIKV) and chikungunya virus (CHIKV) caused explosive outbreaks in 2013-2014 (42) and 2014-2015 (43), respectively. During the ZIKV outbreak, severe neurologic complications in adults (44) and central nervous system

175 malformations in newborns and fetuses (45) were recorded. In addition to arboviral diseases, CDs 176 caused by respiratory viruses have become major health concerns over the past decades. Several 177 epidemics of variable severity caused by influenza A and/or B viruses have been reported in French Polynesia (29). While influenza was not considered a public health priority until the early 2000s, an 178 179 epidemic caused by the influenza A virus subtype H1N1 highly affected the population of French 180 Polynesia in 2009, with 13 severe cases requiring hospitalization in a critical care service and 7 deaths 181 recorded (46). More recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 182 reached French Polynesia in March 2020 and caused several epidemic waves, with a total of 78,864 confirmed cases, 3,315 hospitalizations and 783 deaths reported as of August 31, 2022. A serosurvey 183 184 conducted at the end of 2021, from a representative sample of the adult population of Tahiti, found that 57.7% of the study participants had been infected by SARS-CoV-2 during the first two epidemic waves 185 186 (47).

187 Bacterial infections also represent a significant risk for the population of French Polynesia. The 188 incidence of leptospirosis, a rodent-borne disease caused by bacteria belonging to the order 189 Spirochaetales, exploded in 2017 with a rate of 72/100,000 inhabitants (48). Moreover, the incidence 190 of Staphylococcus aureus (S. aureus) infections was estimated at 38/100,000 inhabitants in 2008, and 191 this bacterium was shown to be responsible for one third of the community bacterial infections 192 documented in French Polynesia. The proportion of S. aureus strains resistant to methicillin increased 193 from less than 10% in 1995 to more than 35% in 2001 (49). French Polynesia is also characterized by 194 the unusual high prevalence of acute rheumatic fever associated with infection by Group A 195 streptococcus, with an incidence of 0.06% and a prevalence of 1.29% reported in 2015 (29, 50).

196 Although data exist on the levels of exposure of the population and the risk factors associated 197 with NCDs and CDs in French Polynesia, these data are often old, fragmentary and concern a few 198 islands. Moreover, genomic data, based on whole-genomes, from the Polynesian populations are 199 lacking, precluding a comprehensive assessment of the settlement history of the various islands and 200 archipelagoes, and of the history of adaptation of these populations to island environments - an 201 information that should be of great benefit for the study of the genetic basis of certain diseases that 202 present high incidence in the region. Here we describe the MATAEA project, a wide cross-sectional 203 population-based survey designed to investigate the determinants of health in the adult population of 204 French Polynesia, using a combination of data obtained from a questionnaire, physical measurements, 205 and biological analyses in 2100 inhabitants of 18 different islands distributed among the five 206 archipelagoes.

207

208 STUDY OBJECTIVES

209 MATAEA is a Tahitian compound word ("MATA" means "eye" and "EA" means "health") which can 210 be translated by "take a look at health". The first objective of the MATAEA project was to collect a 211 wide range of data from a large number of inhabitants to assess the health status of the adult population 212 of the five French Polynesian archipelagoes, and identify risk factors for NCDs and CDs related to the 213 specific living context (including the lifestyle, place of residence, history of infections) and intrinsic 214 characteristics of individuals (such as genetics, age, sex, oral and gut microbiome). Results will be 215 made available to health authorities for them to adapt actions and preventive measures to better reduce 216 diseases incidence. The second objective of the project was to use genomic data obtained from the 217 residents to increase our understanding of the history of the settlement of the French Polynesian islands, 218 and to identify the major demographic and adaptive events that may explain the current incidence of 219 some NCDs, and the higher susceptibility to certain NCDs and CDs. Although designed as a general-220 purpose survey with a broad scope, topics identified as major public health issues will be given priority 221 treatment by specialized laboratories involved in the project, as described below.

First, prevalence data for metabolic diseases (including obesity and diabetes) dating from 2010 will be updated (14), and their associated risk factors (such as dietary habits, physical activity, blood

pressure, high blood sugar, excess body fat around the waist, abnormal cholesterol or triglyceride level,
 genetic susceptibility factors, microbiome composition) will be investigated.

226 Second, the seroprevalence of mosquito-borne diseases known to have previously circulated in 227 French Polynesia (including the four serotypes of dengue, Zika and chikungunya) will be measured as 228 previously published (51, 52), to assess the risk for new outbreaks to occur. In addition, the prevalence 229 of filarial antigenemia will be evaluated to check whether the elimination threshold recommended by 230 the WHO has been reached in all archipelagoes, subsequent to the strengthening of community 231 treatment in islands most affected by Bancroftian lymphatic filariasis (35). Risk factors for those 232 mosquito-borne diseases will also be sought. Among them, the level of exposure of the population to 233 mosquito bites will be measured by analyzing the presence of antibodies targeting mosquito salivary 234 proteins in the blood of participants, as previously described (53).

Third, screening for HBsAg and anti-HBV antibodies will be performed to assess the prevalence of current and past HBV infections among the inhabitants of the five archipelagoes, especially those with increased risk factors such as being borne before 1995 and living in the Austral archipelago. As there is no available data regarding the prevalence of hepatitis C virus (HCV) infections in French Polynesia, the presence of anti-HCV antibodies will also be tested.

240 Fourth, concentrations of several heavy metals (including mercury and lead) and pesticides will 241 be measured in the blood of inhabitants of the five archipelagoes to assess the degree of environmental 242 contamination and the risk for human health. Data collected in the questionnaire, such as the island of 243 residence and dietary habits, will be used to identify risk factors associated with contamination with 244 toxic metals and pesticides, as well as ciguatera poisoning. As there is no confirmatory test available 245 to detect current or past ciguatera poisoning, estimate of the prevalence of this disease in the population 246 of the five archipelagoes will be based on the information self-reported by the participants in the 247 questionnaire.

Fifth, as SARS-CoV-2 was introduced into French Polynesia during the participants' inclusion period and a large number of cases with mild or no symptoms might have not been reported, the presence of specific antibodies will be analyzed in the blood samples of participants to evaluate the real proportion of the population infected in the different archipelagoes after the emergence of the virus.

253 Sixth, serological analyzes will be conducted for a panel of viruses known to regularly cause 254 infections in French Polynesia (such as influenza viruses, human immunodeficiency virus, rotaviruses 255 and enteroviruses), but for which there is little data on the immune status of the population.

Finally, the seroprevalence of rodent-borne pathogens including Hantaviruses will be determined, as the high incidence of leptospirosis suggests that other diseases transmitted by rodents may circulate in French Polynesia. The only serosurvey of hantavirus infections in French Polynesia was conducted in 1989 and found specific antibodies in a few samples from rats and humans (54). Consequently, data collected in the present study will allow to detect possible silent circulation of Hantaviruses.

262

263 MATERIALS AND METHODS

264

265 Sampling Design

The MATAEA project is a cross-sectional population-based survey conducted on a random sample of the general population aged from 18 to 69 years, representative of the five archipelagoes of French Polynesia. The sampling protocol is based on the previous population census dating from 2017 (1). A sample with a target size of 2100 participants, equally divided into three age groups (18-29, 30-44 and 45-69), with a sex ratio of 1:1, was established. To represent all archipelagoes, French Polynesia was stratified into three geographical strata: Windward Islands (Society archipelago), Leeward Islands

272 (Society archipelago), and other archipelagoes (Tuamotu, Gambier, Marquesas and Austral), which

273 respectively include 75%, 13% and 12% of the population (Table 1). Since the population size in the 274 Windward Islands is much higher than in the Leeward Islands and in the other archipelagoes, the 275 sample size was amplified in the latter two strata to keep sufficient precision around prevalence 276 estimates for the health conditions under consideration. Consequently, the same sample size of 700 277 subjects was chosen for the three strata, allowing a precision never exceeding +/- 3.7% around 278 prevalence estimates within each strata. In each strata, for convenient reasons, the most populated 279 islands with a health care center and an airport with regular flight rotations were selected for the study, 280 and the number of participants to be recruited was proportional to the population size of the islands as 281 detailed in Table 1. In each island, households were randomly selected by the *Institut de la Statistique* 282 de la Polynésie francaise (ISPF, Tahiti), and in each household one resident meeting the criteria of age 283 and sex sought for the study was recruited.

284

285 Study timeline

286 The recruitment of participants in the 18 islands selected for the study was initially planned from 287 November 2019 to June 2020. However, following the introduction of SARS-CoV-2 in French 288 Polynesia in March 2020, several interruptions occurred during the recruitment phases and the 289 sampling period lengthened (Figure 2). The first break was caused by the population lockdown 290 implemented from March 20 to May 21, 2020. Inclusions resumed in June 2020 but stopped the 291 following month due to the occurrence of a first epidemic wave caused by the original Wuhan strain. 292 Inclusions resumed once again in April 2021 but stopped during August and September 2021, because 293 of a second epidemic wave caused by the Delta variant. The last recruitments were performed from 294 October to December 2021.

295

296 Inclusion/exclusion criteria

The study enrolled men and women aged from 18 to 69 years at the time of enrollment, who had been residing in French Polynesia for at least six months, were affiliated to the French Polynesia social security or assimilated regimens, and were able to provide a written informed consent. Were excluded from the study the minors, pregnant or parturient women, persons deprived of their liberty by a judicial or administrative decision, adults being subject to a legal protection measure or unable to express their consent, people undergoing psychiatric care, people not affiliated to the French Polynesia social security or assimilated regimens, disabled people, and the homeless.

304

305 Participant recruitment and informed consent

306 Each household randomly selected for the study was visited by trained staff from the Institut Louis 307 Malardé (ILM, Tahiti), and only one resident was recruited in the household. Detailed information on 308 the purpose and procedures of the study were provided, to the individual selected, by the ILM staff. 309 Then, signed written informed consent was obtained from the participant. Participation in the study 310 involved agreeing to answer a questionnaire, to undergo physical measurements (height, weight, waist 311 circumference, arterial pressure, and skin pigmentation), and to provide biological samples (blood, 312 saliva, and optionally stool), as detailed in the next sections. The participant answered the questionnaire 313 during face-to-face interview, and answers were reported on an electronic tablet device. Then, the 314 participant was invited to provide a stool sample and was given a collection tube in case of acceptance. 315 Finally, an appointment with a nurse was scheduled one to three days later, in the morning, to collect 316 physical measurements and biological samples. The participant was asked to fast for at least 8 hours 317 and to collect and store the stool sample in a fridge within 24 hours before the visit of the nurse.

Participants received no financial compensation. However, they freely benefited from the results of the anthropometric, blood pressure and fasting blood glucose measurements collected by the nurse, and of the hematology and biochemistry analyses performed from their blood samples at the

- 321 clinical laboratory of ILM. Moreover, and importantly, participants were informed if any atypical result
- 322 was detected and were subsequently guided through a visit to a physician.
- 323

324 Questionnaire

Case report forms (CRF) were built with ODK Collect (Get ODK Inc., USA) which is an open-source mobile client. The CRF consisted of 216 items divided into three major sections: socio-demographic status, lifestyle behaviors, and general health and medical history. It contained questions from the standardized STEPS questionnaire of the WHO designed to monitor the main NCDs risk factors (55), and additional questions specific to the context of French Polynesia. Questions related to COVID-19

- 330 were added in the questionnaire in April 2021. The detailed CRF is available in Supplemental Data 1.
- 331

332 **Physical measurements**

333334 Anthropometric measurements

Anthropometric measurements Anthropometric measurements included height, weight and waist circumference. Standing height was measured in centimeters (cm) with a portable stadiometer (SECA, model 213, France). Weight was measured in kilograms (kg) using a portable electronic weighting scale (SECA, model 813, France). Waist circumference was measured in cm using a constant tension tape (SECA, model 203 measuring tape, France) at the midpoint between the lowest rib and above the iliac crest. Body mass index (BMI) was calculated as weight (in kg) divided by height (in m) squared. BMI values were categorized according to standardized criteria (56).

342

343 **Blood pressure measurements**

Blood pressure was measured on the left arm at heart level using an automatic digital blood pressure monitor (Omron model HBP-1320, Omron Healthcare Co., Japan). The first measurement was performed after the participant rested for 15 min in a sitting position, then two additional measurements were performed 3 minutes apart. Results of the systolic and diastolic pressures were expressed in millimeter of mercury (mmHg).

349

350 Skin pigmentation measurements

Skin pigmentation was measured on the inner arm between biceps and triceps using the DSM III Skin colorimeter (Cortex technology, Denmark). Four measurement replicates were performed for each participant. Colors were quantified using the L*, a*, and b* parameters defined by the International commission on illumination (CIE, Vienna, Austria), where L* measures the degree of brightness or whiteness, a* the degree of redness, and b* the yellowness. Skin erythema 'E' and melanin content 'M' were also measured (57, 58).

357

358 **Biological sample collection and biobanking**

359

360 **Blood**

A capillary whole blood sample was collected at the finger tip of each fasting participant using microtainer contact-activated lancets (Becton Dickinson, USA), and was immediately used for the measurement of blood glucose concentration (mg/dL) with the Freestyle Optium Neo H point-of-care device (Abbott Diabetes Care, France).

Blood samples were also collected by venipuncture in four 5 mL serum separation tubes, and in two 5 mL EDTA tubes (Becton Dickinson, USA). Serum separation tubes and EDTA tubes were maintained at 4 °C until centrifugation during 15 minutes at 3,500 and 2,000 rpm, respectively. Part of the serum and plasma samples were used by the clinical laboratory of ILM to measure several hematological and biochemical parameters as described in Table 2. The remaining samples of serum,

plasma and red blood cell pellets were aliquoted in several tubes and stored at -20 °C until processing
 as detailed in Table 3.

372

383

373 *Saliva*

A 2 mL sample of saliva was self-collected by each participant in an Oragene DNA tube pre-filled with
2 mL of stabilization liquid following the manufacturer's protocol (DNA Genotek, Canada). After
gentle mix, the sample tube was stored at 4 °C until processing (Table 3).

377378 *Stool*

Stool samples were self-collected by participants in tubes pre-filled with 8 mL of DNA stabilization buffer following the manufacturer's instructions (Canvax Biotech, Spain), and stored in a fridge within 24 hours before the appointment with the nurse. Then, stool samples were stored at 4 °C until shipment to ILM. Upon reception at ILM, stool samples were stored at -20 °C until processing (Table 3).

384 Data management

385 The data flow and processing of biological samples are detailed in Figure 3.

Each participant was assigned a unique identification number to anonymize the information collected in the CRF and biological samples. Personal identifying information such as last name, first name, and phone number only appeared on the consent form, which has been kept in a secure location accessible only to the biologists of the clinical laboratory of ILM.

390 Data collected in the CRF were transferred from electronic tablets to a password-protected 391 ODK Aggregate server (Version 2.0.5, Get ODK Inc., USA). Then, these data were uploaded to a 392 password-protected Redcap server (Version 9.5.11, Vanderbilt University, USA) used to aggregate all 393 data from each participant. Results of hematological and biochemical analyses performed by the 394 clinical laboratory of ILM were also uploaded to the Redcap server, and linked to questionnaire data 395 using the unique identification number of each participant. The results of the analyses that will be 396 performed later from the biological samples of the participants will also be uploaded to the Redcap 397 server. All collaborators of the MATAEA project were given a personal and unique login and password 398 to access data in the Redcap server.

The staff of ILM received training on ethical procedures and measures to protect confidentiality needed, and was required to sign a confidentiality agreement form. The Redcap database was validated according to the guidelines of the French National Commission of Data Protection and Individual Liberties, allowing collaboration with external researchers and collaborators.

404 Data Analysis

403

405 According to the data retrieved from the participants, indicators will be defined to identify subjects 406 suffering from, or having a history, of any pathology targeted by the study.

For continuous data, summary statistics will include the arithmetic mean with 95% confidence interval (CI) or standard deviation (SD), or median with inter quartile range. For categorical data, frequency counts, percentages, and 95% CIs will be presented. The characteristics of the subjects will be compared according to sex, age category, and geographical area using the chi-square test for the categorical variables, and using the analysis of variance (ANOVA) for the continuous variables.

412 Non-standardized and standardized (weighted) results will be provided. Weights will be 413 estimated by archipelago (except the Society archipelago for which the Windward Islands and Leeward 414 Islands will be treated separately) and will correspond to the inverse of the probability for each subject 415 to be selected, where the probability in a given archipelago is the number of subjects in each of the 6 416 age/sex strata divided by the total number population in that strata.

417 Risk factors associated with each pathology (if the prevalence is high enough to justify a 418 statistical analysis) will be identified using a logistic regression model. The factors investigated will

- 419 include age, sex, and all other relevant factors. These analyses will account for the sampling plan420 through consideration of survey weights.
- 421

422 Return of individual results to participants

- Results of physical measurements performed by a nurse were provided to each participant during the appointment. If any abnormal result was detected, the nurse advised the participant to consult a doctor immediately.
- 426 Results of hematological and biochemical analyses performed by the clinical laboratory of ILM from
- 427 blood samples of each participant were available on a secured server. Participants could retrieve these
- 428 results online using individual login valid for seven days, or anytime at ILM providing proof of identity.
- 429 If any abnormal result was detected, the participant or the participant's attending doctor (depending on
- 430 the participant's choice as indicated in the informed consent) was notified by a biologist of the clinical
- 431 laboratory of ILM.
- 432 Participants will not be informed of individual research results that will be obtained by the specialized
- 433 laboratories involved in the MATAEA project. However, if any research result suggests an underlying
- 434 pathology, the participant or the participant's attending doctor (depending on the participant's choice
- 435 as indicated in the informed consent) will be notified by a biologist of the clinical laboratory of ILM
- 436 to carry out additional investigations.437

438 STRENGHS AND LIMITATIONS

- 439 The MATAEA project is the first cross-sectional survey designed to investigate a broad range of health 440 issues in the five archipelagoes of French Polynesia. The high number of participants and their wide 441 geographical distribution guarantee a good representativeness of the population of French Polynesia. 442 The large amount of data obtained for each participant from the CRF, physical measurements and 443 biological analyses will make it possible to update the information on the prevalence of numerous 444 NCDs and CDs known as major public health concerns in French Polynesia, and possibly identify 445 specific indicators and/or risk factors for these diseases. The study will also provide new 446 epidemiological information on poorly studied or unknown pathologies. Finally, the MATAEA project 447 will generate a high amount of genetic data for a population that has been so far poorly represented in human genetic studies. 448
- 449 Nevertheless, the MATAEA project has some limitations that should be acknowledged. First, 450 the population aged under 18 years was not included to the survey, which might have an impact on the 451 estimate of the prevalence of certain pathologies. Second, participants were recruited in only 18 of the 452 75 inhabited islands while differences may exist between the inhabitants of distinct islands within the 453 same archipelago. Third, there might be an underrepresentation of hard-to-reach subjects, such as 454 heavy drinkers or socially excluded persons, which might be more prone to some pathologies. Fourth, 455 the number of participants recruited for the study may be not sufficient to investigate rare pathologies. 456 Fifth, the cross-sectional nature of the survey does not allow to examine the temporal relationship 457 between exposures and diseases under study. Finally, the sampling period has been interrupted three 458 times because of the COVID-19 pandemic and more than two years elapsed between the first and last 459 inclusion (Figure 2).
- 460

461 COMMUNITY ENGAGEMENT

The main objectives of the MATAEA project have already been presented to the Health and Research authorities of French Polynesia as well as, in several occasions, to the general French Polynesian populations, in particular in the form of conferences principally conducted by Van-Mai Cao-Lormeau

- 465 and Lluis Quintana-Murci. Furthermore, a video presenting the MATAEA project is already accessible 466 online (https://youtube.com/playlist?list=PLVLsoPZrkK4ipioiTOhGh0z05XZSHPC6H). All the
- 467 results generated in the framework of the MATAEA project will be also made available to the

468 population of French Polynesia through various communication channels. The results will be presented

- 469 in an accessible way for the public, through conferences, seminars, and roundtables, and will be sent
- to the mayors of the islands that participated in the study to be relayed to the community. Finally, the
- public will be informed of the results published in scientific journals through popularized summariestranslated into both French and Tahitian.
- 473

474 ETHICS STATEMENT

- This study involving human participants was approved by the *French Comité de protection des personnes* (CPP - OUEST III no. 19.08.60 / SI CNRIPH 19.07.02.38421) and the *Comité d'Ethique de la Polynésie française* (Avis no. 80 CEPF-03/09/2019). Written informed consent was obtained from all participants. People who were unable to express their consent or answer the questionnaire were excluded from the study. Data collection, storage, transfer and process were executed according to the
- 480 European general data protection regulation procedures.
- 481

482 **CONFLICT OF INTEREST**

- The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.
- 485

486 AUTHOR CONTRIBUTIONS

AF, LQM, AS, and VMCL designed and conceptualized the project; AF, LQM, EP, AS, JV, NP, JT,
SO, SL, HB, PB, CG, ES, BC and PA participated in the design of the study protocol; IT, MA, and
VMCL wrote the study protocol; SFP and NJ managed the ethical aspects of the project; NP and JT
carried out the draw of participants; IT, MA, and VMCL supervised and coordinated the project; IT,
EP, AJ, MR, VM, and KC performed the data management; CH and AB processed biological samples;
GRL, DL and EP designed genetic analyses; VMCL acquired funding for the project; IT and MA
drafted the manuscript. All authors read and approved the submitted version of the manuscript.

495 FUNDING

The MATAEA project received financial support from *La Délégation à la Recherche de la Polynésie française* (Convention no. 03557/MED/REC du 29 mai 2019) and the *Contrat de Projet Etat-Pays*2015-2020 (Arrêté no. HC/372/DIE/BPT du 18 mai 2018; Convention no. 03298/MTF/REC du 17 mai
2018). The costs related to the shipping and analysis of the samples will be borne by the laboratories
involved in the project.

500 501

502 ACKNOWLEDGEMENTS

We thank the staff of all the laboratories that contributed to the realization of this study. We also acknowledge the municipal staff and the guides in the islands selected for the study for their support in recruiting participants. Finally, we especially thank all the individuals who willingly agreed to participate in this study

509 Table 1. Geographical distribution of the 2,100 participants randomly selected for the

510 MATAEA project

511

Strata			Archipelago	Island		
Name	Population size (%)*	Sample size	Name	Name	Population size (%)*	Sample size
Windward	207,333	700	Society	Tahiti	189,517 (91%)	637
Islands	Islands (75%)			Moorea	17,816 (9%)	63
Leeward Islands	35,393 (13%)	700	Society	Raiatea	12,249 (36%)	252
				Bora Bora	10,549 (31%)	217
				Tahaa	5,234 (15%)	105
				Huahine	6,075 (18%)	126
Others archipelagoes	33,192 (12%)	700	Tuamotu	Rangiroa	3,657 (16%)	112
				Fakarava	1,637 (7%)	49
				Hao	1,258 (5%)	35
				Makemo	1,508 (6%)	42
			Gambier	Mangareva	1,535 (7%)	49
			Marquesas	Nuku Hiva	2,951 (13%)	91
				Hiva Oa	2,243 (10%)	70
				Ua Pou	2,213 (9%)	63
			Austral	Tubuai	2,217 (9%)	63
				Rurutu	2,466 (10%)	70
				Raivavae	903 (4%)	28
				Rimatara	872 (4%)	28
Total	275,918	2,100				2,100

512

513 * data from the population census of 2017 (59)

514 Table 2. List of hematological and biochemical parameters analyzed for the MATAEA project

Group	Measured parameter	Units	Test	Analyzer
Complete blood count	Hemoglobin	g/dL	Spectrophotometry	XT-4000 or XN- 1000, Sysmex (France)
	Hematocrit	%	Electrical impedance	XT-4000 or XN- 1000, Sysmex (France)
	Leucocytes count	G/L	Fluorocytometry	XT-4000 or XN- 1000, Sysmex (France)
	Neutrophils count	G/L or %	Fluorocytometry	XT-4000 or XN- 1000, Sysmex (France)
	Eosinophils count	G/L or %	Fluorocytometry	XT-4000 or XN- 1000, Sysmex (France)
	Lymphocytes count	G/L or %	Fluorocytometry	XT-4000 or XN- 1000, Sysmex (France)
	Monocytes count	G/L or %	Fluorocytometry	XT-4000 or XN- 1000, Sysmex (France)
	Platelets count	G/L	Electrical impedance	XT-4000 or XN- 1000, Sysmex (France)
	Mean platelet volume	fL	Electrical impedance	XT-4000 or XN- 1000, Sysmex (France)
	Red blood cells count	T/L	Electrical impedance	XT-4000 or XN- 1000, Sysmex (France)
	Red blood cell distribution width	_	Electrical impedance	XT-4000 or XN- 1000, Sysmex (France)
	Mean corpuscular volume	fL	Electrical impedance	XT-4000 or XN- 1000, Sysmex (France)
	Mean corpuscular hemoglobin	pg/cell	Spectrophotometry	XT-4000 or XN- 1000, Sysmex (France)
	Mean corpuscular hemoglobin concentration	g/dL	Spectrophotometry	XT-4000 or XN- 1000, Sysmex (France)
Comme	Serum aspect	-	Visual assessment	-
Serum aspect	Serum index	UI	Spectrophotometry	Cobas c501, Roche (Switzerland)

medRxiv preprint doi: https://doi.org/10.1101/2023.04.05.23288204; this version posted April 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license. It is made available under a CC-BY-ND 4.0 International license.

			1	
Diabetes	Glycated	0/		Capillarys 2 Flex
	hemoglobin	%		Piercing, SEBIA
	A1c		Capillary eletrophoresis	(France)
	Fasting blood			Optium Neo H,
	glucose level			Abbott Diabetes
	e	mg/dL	Fingertip lancing technique	Care (France)
	Total	mmol/l		Cobas c501, Roche
	cholesterol		Enzymatic colorimetric assay	(Switzerland)
	HDL-	mmol/l	Homogenous enzymatic colorimetric	Cobas c501, Roche
Linida	cholesterol	IIIII0I/I	assay	(Switzerland)
Lipids	LDL-	mmo1/1		Cobas c501, Roche
	cholesterol	mmol/l	Friedewald formula (60)	(Switzerland)
	Trialmonidos	mmol/l		Cobas c501, Roche
	Triglycerides		Enzymatic colorimetric assay	(Switzerland)
	Creatinine	µmol/L		Cobas c501, Roche
Kidney			Enzymatic colorimetric assay	(Switzerland)
function	Glomerular	mL/min/1.73	Chronic Kidney Disease Epidemiology	Cobas c501, Roche
	filtration rate	m²	Collaboration (CKD-EPI) formula (61)	(Switzerland)
	Aspartate			
	aminotransfer	UI/L		Cobas c501, Roche
	ase		Enzymatic colorimetric assay	(Switzerland)
	Alanine		· · · · ·	
	aminotransfer	UI/L		Cobas c501, Roche
Liver and	ase		Enzymatic colorimetric assay	(Switzerland)
inflammati	Gamma		· · · ·	
on	glutamyl	UI/L		Cobas c501, Roche
	transferase		Enzymatic colorimetric assay	(Switzerland)
		µmol/L		Cobas c501, Roche
	Total bilirubin		Photometry assay	(Switzerland)
	C-reactive	mg/L	Particle-enhanced immunoturbidimetric	Cobas c501, Roche
	protein		assay	(Switzerland)

517 Table 3. List of laboratory analyses planned in the MATAEA project

518

Sample type	Analysis	Laboratory
Serum and plasma	Hematological and biochemical analyses	LABM, ILM, Tahiti, French Polynesia
Serum	Arbovirus serology	LIV, ILM, Tahiti, French Polynesia
Serum	Mosquito saliva serology	LEM, ILM, Tahiti, French Polynesia
Serum	Hantavirus serology	EIRU, IP, Paris, France
Serum	VirScan (62)	HEGU, IP, Paris, France
Plasma	Hepatitis B and C serologies	CHPF, Tahiti, French Polynesia
Plasma	Pesticides quantitation	INSPQ, Montreal, Canada
Red blood cells pellet	Heavy metals quantitation	INSPQ, Montreal, Canada
Red blood cells pellet, saliva	Genetic analysis	HEGU, IP, Paris, France
Saliva	Oral microbiome analysis	HEGU, IP, Paris, France
Stool	Intestinal microbiome analysis	HEGU, IP, Paris, France

519 LABM: Clinical Laboratory; ILM: Institut Louis Malardé; LIV: Laboratory of research on emerging

520 viral diseases; LEM: Laboratory of research in medical entomology; IP: Institut Pasteur; EIRU:

521 Environment and Infectious Risk Unit ; HEGU : Human Evolutionary Genetics Unit ; CHPF: Centre

522 Hospitalier de la Polynésie française; INSPQ: Institut National de Santé Publique du Québec.

524 **References**

- 525 1. Institut de la Statistique de la Polynésie française. Points fort de la Polynésie française, Le 526 recensement de la population en Polynésie française en 2017. (2018). Available online at:
- 527 https://data.ispf.pf/docs/default-source/publi-pf-bilans-et-etudes/pf-etudes-7-2018-rp-
- 528 <u>2017.pdf?sfvrsn=8</u> (Accessed March 20, 2023).
- 529 2. Gosling AL, Matisoo-Smith EA. The evolutionary history and human settlement of Australia 530 and the Pacific. Curr Opin Genet Dev. 2018;53:53-9. doi: 10.1016/j.gde.2018.06.015.
- Joannidis AG, Blanco-Portillo J, Sandoval K, Hagelberg E, Barberena-Jonas C, Hill AVS, et
 al. Paths and timings of the peopling of Polynesia inferred from genomic networks. Nature.
 2021;597(7877):522-6. doi: 10.1038/s41586-021-03902-8.
- Choin J, Mendoza-Revilla J, Arauna LR, Cuadros-Espinoza S, Cassar O, Larena M, et al.
 Genomic insights into population history and biological adaptation in Oceania. Nature.
 2021;592(7855):583-9. doi: 10.1038/s41586-021-03236-5.
- 5. Hudjashov G, Endicott P, Post H, Nagle N, Ho SYW, Lawson DJ, et al. Investigating the
 origins of eastern Polynesians using genome-wide data from the Leeward Society Isles. Sci Rep.
 2018;8(1):1823. doi: 10.1038/s41598-018-20026-8.
- 540 6. Kirch PV. Modern Polynesian genomes offer clues to early eastward migrations. Nature.
 541 2021;597(7877):477-8. doi: 10.1038/d41586-021-01719-z.
- 542 7. Horwood PF, Tarantola A, Goarant C, Matsui M, Klement E, Umezaki M, et al. Health
 543 Challenges of the Pacific Region: Insights From History, Geography, Social Determinants, Genetics,
 544 and the Microbiome. Front Immunol. 2019;10:2184. doi: 10.3389/fimmu.2019.02184.
- 5458.Barreiro LB, Quintana-Murci L. Evolutionary and population (epi)genetics of immunity to546infection. Hum Genet. 2020;139(6-7):723-32. doi: 10.1007/s00439-020-02167-x.
- 9. Quach H, Rotival M, Pothlichet J, Loh YE, Dannemann M, Zidane N, et al. Genetic
 Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. Cell.
 2016;167(3):643-56.e17. doi: 10.1016/j.cell.2016.09.024.
- 550 10. Quintana-Murci L. Human Immunology through the Lens of Evolutionary Genetics. Cell.
 551 2019;177(1):184-99. doi: 10.1016/j.cell.2019.02.033.
- 552 11. Gouvernement de la Polynésie française. La politique de santé de la Polynésie française 553 Orientations stratégiques 2016-2025. (2016). Available online at: <u>https://www.service-</u>
- 554 public.pf/dsp/wp-content/uploads/sites/12/2017/06/La-politique-de-Sante%CC%81-en-PF-2016 555 <u>2025-web.pdf</u> (Accessed March 20, 2023).
- Institut de la Statistique de la Polynésie française. Bilan démographique 2020. (2021).
 Available online at:
- 558 <u>https://www.ispf.pf/content//uploads/1256_Bilan_demographique_2020_f9055f2afa.pdf</u> (Accessed
 559 March 20, 2023).
- 13. Reeve E, Lamichhane P, McKenzie B, Waqa G, Webster J, Snowdon W, et al. The tide of
- dietary risks for noncommunicable diseases in Pacific Islands: an analysis of population NCD
- 562 surveys. BMC Public Health. 2022;22(1):1521. doi: 10.1186/s12889-022-13808-3.
- 563 14. Bertrand S, Berry A-L. Enquête santé 2010 en Polynésie française : surveillance des facteurs
 564 de risque des maladies non transmissibles. Bull Épidémiol Hebd. 2013;28-29:326-32.

- 565 15. Direction de la Santé. Statistiques des causes de décès en Polynésie française 2011-2015.
- 566 (2019). Available online at: <u>https://www.service-public.pf/dsp/wp-</u>
- 567 <u>content/uploads/sites/12/2020/02/Rapport_-StatistiquesCausesDC2011_15PF.pdf</u> (Accessed March 20, 2023).
- 569 16. Institut d'Emission d'Outre-Mer. Rapport annuel 2017 de l'IEOM Polynésie française.
- 570 (2018). Available online at:
- 571 <u>https://www.ieom.fr/IMG/pdf/rapport_annuel_2017_ieom_polynesie_francaise_-juin_2018.pdf</u> 572 (Accessed March 20, 2023).
- 573 17. Direction de la Santé. Cancers en Polynésie française Statistiques du Registre des cancers.
- 574 (2016). Available online at: <u>https://www.service-public.pf/dsp/wp-</u>
- 575 <u>content/uploads/sites/12/2021/12/Rapport-cancer-PF-2016-.pdf</u> (Accessed March 20, 2023).
- 576 18. Tervonen H, Foliaki S, Bray F, Roder D. Cancer epidemiology in the small nations of Pacific
 577 Islands. Cancer epidemiology. 2017;50(Pt B):184-92. doi: 10.1016/j.canep.2017.09.002.
- 578 19. World Health Organisation. Global Cancer Observatory French Polynesia in 2020. (2021).
- Available online at: <u>https://gco.iarc.fr/today/data/factsheets/populations/258-french-polynesia-fact-</u>
 <u>sheets.pdf</u> (Accessed March 20, 2023).
- 581 20. Condat B, Lascols A, Lutringer-Magnin D, Chakhtoura F, Lastere S, Bronstein J.
- 582 Épidémiologie du carcinome hépatocellulaire en Polynésie française. Bull Épidémiol Hebd.
 583 2022;16:280-7.
- 584 21. Chinain M, Gatti CM, Roué M, Darius HT. Ciguatera poisoning in French Polynesia: insights
 585 into the novel trends of an ancient disease. New microbes and new infections. 2019;31:100565. doi:
 586 10.1016/j.nmni.2019.100565.
- 587 22. Chinain M, Gatti CM. Surveillance de la ciguatéra en Polynésie française Bilan 2021.
- 588 (2022). Available online at: <u>https://ciguatera.pf/images/BILAN_CIGUATERA_PF_2021_.pdf</u>
 589 (Accessed March 20, 2023).
- 590 23. St-Jean A, Suhas E, De Pina JJ, Cordier S, Lucas M, Ayotte P. Exposure to toxic metals and
 591 polychlorinated biphenyls of adolescents and adults from two atolls in the Tuamotu Archipelago
- 592 (French Polynesia). The Science of the total environment. 2019;695:133791. doi:
- 593 10.1016/j.scitotenv.2019.133791.
- 594 24. Dewailly E, Chateau-Degat L, Suhas E. Fish consumption and health in French Polynesia.
 595 Asia Pacific journal of clinical nutrition. 2008;17(1):86-93.
- 596 25. Dewailly E, Suhas E, Mou Y, Dallaire R, Chateau-Degat L, Chansin R. High fish
 597 consumption in French Polynesia and prenatal exposure to metals and nutrients. Asia Pacific journal
 598 of clinical nutrition. 2008;17(3):461-70.
- Solution of Coral reefs
 Roche H, Salvat B, Ramade F. Assessment of the pesticides pollution of coral reefs
 communities from French Polynesia. Revue d'Ecologie (Terre Vie). 2011;66(1):3-10. doi:
 10.3406/revec.2011.1553.
- 602 27. Salvat B, Roche H, Berny P, Ramade F. Recherches sur la contamination par les pesticides
 603 d'organismes marins des réseaux trophiques récifaux de Polynésie Française. Revue d'Ecologie
 604 (Terre Vie). 2012;67(2):129-47. doi: 10.3406/revec.2012.1629.
- Salvat B, Roche H, Ramade F. On the occurrence of a widespread contamination by
 herbicides of coral reef biota in French Polynesia. Environ Sci Pollut Res Int. 2016;23(1):49-60. doi:
 10.1007/s11356-015-4395-9.

- 608 29. Hubert B. Situation des maladies infectieuses en Polynésie française en 2001. 2001. doi:
- 609 10.13140/RG.2.1.3451.2804.
- 610 30. Direction de la Santé. La tuberculose en Polynésie française Rapport annuel 2018. (2018).
- Available online at: <u>https://www.service-public.pf/dsp/wp-content/uploads/sites/12/2019/04/Rapport-</u>
 <u>tuberculose-2018.pdf</u> (Accessed March 20, 2023).
- 613 31. Musso D, Rovery C, Loukil A, Vialette V, Nguyen NL. Leprosy in French Polynesia. New
 614 microbes and new infections. 2019;29:100514. doi: 10.1016/j.nmni.2018.10.010.
- 615 32. Ichimori K, Graves PM. Overview of PacELF-the Pacific Programme for the Elimination of 616 Lymphatic Filariasis. Tropical medicine and health. 2017;45:34. doi: 10.1186/s41182-017-0075-4.
- 617 33. Kline K, McCarthy JS, Pearson M, Loukas A, Hotez PJ. Neglected tropical diseases of 618 Oceania: review of their prevalence, distribution, and opportunities for control. PLoS neglected
- tropical diseases. 2013;7(1):e1755. doi: 10.1371/journal.pntd.0001755.
- Mou Y, Plichart C, Legrand A, Mallet H, Cerf N, Nguyen L. Evaluation de la prevalence de
 la filariose lymphatique en 2008 en Polynésie française. Bull Epidémiol Hebd. 2009;48-49-50:504-7.
- 622 35. Segalin JM, Le Calvez E. Programme de lutte contre les maladies tropicales negligées en
- Polynesie française 2019-2023. (2019). Available online at: <u>https://www.service-public.pf/dsp/wp-</u>
- 624 <u>content/uploads/sites/12/2019/11/2019-03-14-PROGRAMME-MTN.pdf</u> (Accessed March 20, 2023).
- 36. Boutin JP, Sainte Marie FF, Cartel JL, Cardines R, Girard M, Roux J. Prevalence of hepatitis
 B virus infection in the Austral archipelago, French Polynesia: identification of transmission patterns
 for the formulation of immunization strategies. Trans R Soc Trop Med Hyg. 1990;84(2):283-7. doi:
 10.1016/0035-9203(90)90288-p.
- 37. Moulia-Pelat J, Spiegel A, Excler J, Martin P, Roux J, Boutin J, et al. Lutte contre l'hépatite
 B en Polynésie française par un programme de vaccination systématique des nouveau-nés avec le
 vaccin Genhevac B[®]. Cahiers d'études et de recherches francophones / Santé. 1996;6(1):11-5.
- 632 38. Gouvernement de la Polynésie Française. Délibération n° 95-63 AT du 23 mai 1995 portant
 633 réglementation des vaccinations contre certaines maladies transmissibles chez l'enfant. (1995).
 634 Available online at:
- 635https://lexpol.cloud.pf/document.php?document=190635&deb=1202&fin=1203&titre=RMOpbGliw6636lyYXRpb24gbsKwIDk1LTYzIEFUIGR1IDIzLzA1LzE5OTU= (Accessed March 20, 2023).
- 637 39. Patel MK, Le Calvez E, Wannemuehler K, Ségalin JM. Hepatitis B Vaccination Coverage
- and Prevalence of Hepatitis B Surface Antigen Among Children in French Polynesia, 2014. The
 American journal of tropical medicine and hygiene. 2016;94(6):1370-5. doi: 10.4269/ajtmh.15-0903.
- 40. Aubry M, Cao-Lormeau VM. History of arthropod-borne virus infections in French
 Polynesia. New microbes and new infections. 2019;29:100513. doi: 10.1016/j.nmni.2019.01.009.
- 41. Aubry M, Mapotoeke M, Teissier A, Paoaafaite T, Dumas-Chastang E, Giard M, et al.
 Dengue virus serotype 2 (DENV-2) outbreak, French Polynesia, 2019. Euro surveillance : bulletin
 Europeen sur les maladies transmissibles = European communicable disease bulletin. 2019;24(29).
 doi: 10.2807/1560-7917.Es.2019.24.29.1900407.
- 646 42. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, et al. Zika virus,
 647 French polynesia, South pacific, 2013. Emerging infectious diseases. 2014;20(6):1085-6. doi:
- 648 10.3201/eid2006.140138.

43. Aubry M, Teissier A, Roche C, Richard V, Yan AS, Zisou K, et al. Chikungunya outbreak,

650 French Polynesia, 2014. Emerging infectious diseases. 2015;21(4):724-6. doi:

651 10.3201/eid2104.141741.

652 44. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain653 Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control
654 study. Lancet (London, England). 2016;387(10027):1531-9. doi: 10.1016/s0140-6736(16)00562-6.

45. Besnard M, Eyrolle-Guignot D, Guillemette-Artur P, Lastère S, Bost-Bezeaud F, Marcelis L,

et al. Congenital cerebral malformations and dysfunction in fetuses and newborns following the 2013

to 2014 Zika virus epidemic in French Polynesia. Euro surveillance : bulletin Europeen sur les
 maladies transmissibles = European communicable disease bulletin. 2016;21(13). doi: 10.2807/1560-

659 7917.Es.2016.21.13.30181.

46. Barboza P, Baudon C, Chérié-Challine L, Gastellu-Etchegorry M, Gueguen J, La Ruche G, et

al. Influenza A(H1N1)2009 in the French Pacific territories: assessment of the epidemic wave during the austral winter. Clinical microbiology and infection : the official publication of the European

- 662 the austral winter. Clinical microbiology and infections ine official publication of the European 663 Society of Clinical Microbiology and Infectious Diseases, 2010;16(4);204.8, doi: 10.1111/j.1460
- 663 Society of Clinical Microbiology and Infectious Diseases. 2010;16(4):304-8. doi: 10.1111/j.1469664 0691.2010.03172.x.

47. Aubry M, Maset N, Chapman L, Simon A, Olivier S, Bos R, et al. Seroprevalence of SARSCoV-2 Antibodies in French Polynesia and Perspective for Vaccine Strategies. Preprints. 2022. doi:
10.20944/preprints202212.0386.v1.

- 48. Direction de la Santé. La leptospirose en Polynésie française Rapport annuel 2018. (2018).
 Available online at: https://www.service-public.pf/dsp/wp-
- 670 <u>content/uploads/sites/12/2022/04/190314_Rapport-leptospirose-2018.pdf</u> (Accessed March 20,
 671 2023).

49. Lévy M, Baudet J, Beau F, Devaud F, Sauget A. Étude de prévalence de la sensibilité aux
antibiotiques de Staphylococcus aureus en Polynésie française, 2006-2008. Bull Epidémiol Hebd
Thématique. 2009;48-49-50:526-28.

50. Leitwein K. Evaluation de la mise en place d'une méthode de dépistage échographique
simplifiée des cardiopathies rhumatismales chroniques chez les élèves de CM2 des années 2012/2013
et 2013/2014 à Moorea en Polynésie Française 2017. Available online at:

678 <u>https://dumas.ccsd.cnrs.fr/dumas-01534602/document</u> (Accessed March 20, 2023).

679 51. Aubry M, Teissier A, Huart M, Merceron S, Vanhomwegen J, Mapotoeke M, et al.

680 Seroprevalence of Dengue and Chikungunya Virus Antibodies, French Polynesia, 2014-2015.
681 Emerging infectious diseases. 2018;24(3):558-61. doi: 10.3201/eid2403.171149.

52. Aubry M, Teissier A, Huart M, Merceron S, Vanhomwegen J, Roche C, et al. Zika Virus
Seroprevalence, French Polynesia, 2014-2015. Emerging infectious diseases. 2017;23(4):669-72. doi:
10.3201/eid2304.161549.

53. Mathieu-Daudé F, Claverie A, Plichart C, Boulanger D, Mphande FA, Bossin HC. Specific
human antibody responses to Aedes aegypti and Aedes polynesiensis saliva: A new epidemiological
tool to assess human exposure to disease vectors in the Pacific. PLoS neglected tropical diseases.
2018;12(7):e0006660. doi: 10.1371/journal.pntd.0006660.

689 54. Chungue E, Rollin PE, Saluzzo JF, Gentile B, Roux JF, Sureau P. Serological survey of
690 Hantavirus infection in French Polynesia. Trans R Soc Trop Med Hyg. 1989;83(2):258. doi:
691 10.1016/0035-9203(89)90669-x.


- 692 55. World Health Organisation. Standard STEPS instrument. (2020). Available online at:
- 693 <u>https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps/instrument</u>
 694 (Accessed March 20, 2023).
- 695 56. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of
 696 a WHO consultation. World Health Organization technical report series. 2000;894:i-xii, 1-253.
- 57. Matias AR, Ferreira M, Costa P, Neto P. Skin colour, skin redness and melanin biometric
 measurements: comparison study between Antera(®) 3D, Mexameter(®) and Colorimeter(®). Skin
 research and technology : official journal of International Society for Bioengineering and the Skin
 (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society
 for Skin Imaging (ISSI). 2015;21(3):346-62. doi: 10.1111/srt.12199.
- 70258.Wong LC, Jamil A, Md Nor N. The effect of pre-phototest sun exposure on minimal
- rythema dose and minimal melanogenic dose among skin phototypes III, IV and V.
- Photodermatology, photoimmunology & photomedicine. 2018;34(6):400-4. doi:
- 705 10.1111/phpp.12410.
- 706 59. Institut de la Statistique de la Polynésie française. Recensement de la population 2017-
- 707 Données détaillées Population par Géographie administrative et par Age décennal. (2018).
- Available online at: <u>https://data.ispf.pf/bases/Recensements/2017/Donnees_detaillees.aspx</u> (Accessed
 March 20, 2023).
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density
 lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem.
- 712 1972;18(6):499-502. doi: 10.1186/s12944-019-1178-1.
- 61. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new
 equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. doi:
 10.7326/0003-4819-150-9-200905050-00006.
- 716 62. Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung'u T, et al. Viral immunology.
- 717 Comprehensive serological profiling of human populations using a synthetic human virome. Science
- 718 (New York, NY). 2015;348(6239):aaa0698. doi: 10.1126/science.aaa0698.
- 719


Figure 1. Map of French Polynesia showing the geographical distribution of the five archipelagoes (Society, Tuamotu, Gambier, Marquesas and Austral) compared to the European continent (showed at the same scale). Flight connections between Tahiti and the islands selected for the survey are indicated by orange lines. Inset map at upper left shows location of French Polynesia (red circle) within the Polynesian triangle (black triangle) bounded by the islands of Hawaii, New Zealand and Easter Island in the Pacific Ocean.

727

Figure 2. Study timeline for the MATAEA project. Recruitment of participants in the 18 islands of

- French Polynesia started on November 4, 2019, and ended on December 8, 2021. Three breaks
- occurred during that period because of SARS-CoV-2 circulation: (1) population lockdown from
- March 20 to May 21, 2020; (2) first epidemic wave due to the SARS-CoV-2 Wuhan strain from
- August 2020 to February 2021; (3) second epidemic wave due the SARS-CoV-2 Delta variant from
- August to September 2021.
- 734 Figure 3. Data flow and biological samples processing for the MATAEA project. LABM: Clinical
- 735 Laboratory; ILM: Institut Louis Malardé; LIV: Laboratory of research on emerging viral diseases; IP:
- 736 Institut Pasteur.
- 737





Second epidemic wave (SARS-CoV-2 Delta variant)

